2788-74-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Ethylamino-3-nitro-benzoic acid is used as an intermediate in the synthesis of various drugs, specifically for the production of anti-inflammatory and analgesic medications. Its unique chemical structure allows it to contribute to the development of effective therapeutic agents.
Used in Dye and Pigment Industry:
4-Ethylamino-3-nitro-benzoic acid is also employed in the manufacture of dyes and pigments. Its ability to impart vibrant colors to products makes it a valuable component in creating visually appealing and long-lasting colorants for various applications.

InChI:InChI=1/C9H10N2O4/c1-2-10-7-4-3-6(9(12)13)5-8(7)11(14)15/h3-5,10H,2H2,1H3,(H,12,13)

Upstream product

• 5429-28-7 4-(diethylamino)benzoic acid 
• 7697-37-2 nitric acid 
• 7647-01-0 hydrogenchloride 
• 861782-56-1 4-(diethyl-oxy-amino)-benzoic acid 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 75-04-7 ethylamine 

Downstream Products

• 91182-00-2 ethyl 4-(ethylamino)-3-nitrobenzoate 
• 3846-50-2 2,4-dinitro-N-ethylaniline 
• 861601-71-0 4-(ethyl-nitroso-amino)-3,5-dinitro-benzoic acid 
• 66315-20-6 3-amino-4-(ethylamino)benzoic acid 
• 861601-78-7 4-(ethyl-nitro-amino)-3,5-dinitro-benzoic acid ethyl ester 
• 1392110-40-5 phenyl 3-nitro-4-(ethylamino)-benzamide 
• 1392110-42-7 3-fluorophenyl 3-nitro-4-(ethylamino)-benzamide 
• 1392110-41-6 phenyl 3-amino-4-(ethylamino)-benzamide 
• 1392110-43-8 3-fluorophenyl 3-amino-4-(ethylamino)-benzamide 
• 299927-14-3 1-ethyl-2-methyl-N-phenyl-1H-benzo[d]imidazole-5-carboxamide 
• 1392110-35-8 1-ethyl-N-(3-fluorophenyl)-2-methyl-1H-benzo[d]imidazole-5-carboxamide 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS

The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series.

1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b

1-Substituted benzotriazole carboxylic acids have been identified as the first reported examples of selective small-molecule agonists of the human orphan G-protein-coupled receptor GPR109b (HM74), a low-affinity receptor for the HDL-raising drug niacin. N

BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF

The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR refer

5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS

Compounds of the formula (I) provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula (I) inhibit PTP-1 B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity.

HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.